KENLIFABI

Serial Number 90827353
606

Registration Progress

Application Filed
Jul 14, 2021
Under Examination
Sep 13, 2022
Approved for Publication
Jul 19, 2022
Published for Opposition
Jul 19, 2022
Registered

Attorney Assistance

Abandonment Notice E-Mailed - No Use Statement Filed
Due: Dec 21, 2025 5 days
Revival assistance for abandoned trademark

Trademark Image

KENLIFABI

Basic Information

Serial Number
90827353
Filing Date
July 14, 2021
Published for Opposition
July 19, 2022
Abandonment Date
October 20, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 20, 2025
Classes
005

Rights Holder

Idorsia Pharmaceuticals Ltd

09
Address
Hegenheimermattweg 91
Allschwil 4123
CH

Ownership History

Idorsia Pharmaceuticals Ltd

Original Applicant
09
Allschwil CH

Idorsia Pharmaceuticals Ltd

Owner at Publication
09
Allschwil CH

Legal Representation

Attorney
Gail I. Nevius Abbas

USPTO Deadlines

Next Deadline
5 days remaining
Abandonment Notice E-Mailed - No Use Statement Filed
Due Date
December 21, 2025

Application History

38 events
Date Code Type Description Documents
Oct 21, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Oct 20, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jul 8, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 7, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Mar 10, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
Jul 7, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Mar 11, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 24, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 18, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Jul 18, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Jul 18, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 28, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 27, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Feb 27, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Feb 27, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 1, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 28, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jul 28, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Jul 28, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 24, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 22, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 22, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 22, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 13, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 19, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 19, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 29, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 15, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 15, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jun 15, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jun 15, 2022 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jun 15, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Apr 11, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 11, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 11, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 4, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 17, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 17, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, and for the treatment of glycolipid storage disorders

Classification

International Classes
005